GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
Thursday, GSK plc (NYSE:GSK) announced headline results of a phase 2 trial for its mRNA seasonal influenza vaccine program.
週四，葛蘭素史克公司（紐約證券交易所代碼：GSK）公佈了其mRNA季節性流感疫苗計劃2期試驗的總體結果。
The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
該試驗研究了老年人和年輕人的一系列mRNA製劑，以評估與目前的護理標準相比，哪些候選疫苗可以改善對甲型和乙型流感菌株的免疫反應。
The data demonstrated positive immune responses against influenza A and B strains compared to the current standard of care, meeting all predefined success criteria in the tested age groups of older and younger adults.
數據顯示，與目前的護理標準相比，對甲型和乙型流感菌株的免疫反應呈陽性，符合老年人和年輕人測試年齡組中所有預定義的成功標準。
Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech.
另請閱讀：葛蘭素史克停止單純皰疹病毒疫苗的開發，爲Moderna、BioNTech等其他競爭者掃清了道路。
Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.
中期數據表明，候選疫苗在所有測試的mRNA製劑中具有可接受的安全性和反應原性。
These results build on the previous phase 2 trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile.
這些結果建立在先前的2期試驗基礎上，並證實了mRNA平台具有很強的總體抗體滴度，並且具有可接受的安全性。
With these results, the GSK mRNA seasonal influenza vaccine program will progress into late-stage clinical development.
有了這些結果，GsK mRNA季節性流感疫苗計劃將進入後期臨床開發階段。
Vaccine candidate based on CureVac N.V.'s (NASDAQ:CVAC) proprietary second-generation mRNA backbone
基於 CureVac N.V. 的候選疫苗s（納斯達克股票代碼：CVAC）專有的第二代 mRNA 骨幹
The Phase 2 study was initiated following interim data reported in April from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza.
2期研究是在4月份報告了正在進行的季節性流感1/2期聯合研究的2期中期數據後啓動的。
In July, GSK and CureVac restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on their respective mRNA development activities.
7月，葛蘭素史克和CureVac將現有的合作重組爲新的許可協議，允許兩家公司優先投資並專注於各自的mRNA開發活動。
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
自2020年以來，葛蘭素史克和CureVac合作開發了用於傳染病的mRNA疫苗。
Price Action: GSK stock is down 0.91% at $43.37, and CVAC stock is down 1.98% at $2.97 at last check Thursday.
價格走勢：週四最後一次檢查時，葛蘭素史克股價下跌0.91％，至43.37美元，CVAC股價下跌1.98％，至2.97美元。
- Nvidia AI Chips Headed to Saudi Arabia, US Reassesses Export Ban
- Nvidia AI 芯片運往沙特阿拉伯，美國重新評估出口禁令
譯文內容由第三人軟體翻譯。